BioVie Inc. has presented new Phase 2 clinical findings showing that its investigational oral drug bezisterim produced statistically significant improvements in motor and non-motor symptoms among patients with early-stage Parkinson’s disease and elevated baseline inflammation. The results, presented at the 2026 American Neurological Association Annual Meeting, suggest that inflammatory biomarkers could help identify patients most likely to benefit from the experimental treatment. The findings strengthen the clinical rationale for targeting neuroinflammation in Parkinson’s disease, although the relatively small study and exploratory nature of several outcomes mean that larger trials are needed to confirm the benefits.
The SUNRISE-PD study evaluated 57 patients over a 12-week treatment period, comparing bezisterim with placebo in individuals who had not previously received carbidopa/levodopa therapy. While several measures favored bezisterim, the most pronounced improvements were concentrated among patients with higher baseline platelet counts, highlighting a potential relationship between systemic inflammation and treatment response.
How did bezisterim improve Parkinson’s disease symptoms in the Phase 2 SUNRISE-PD trial?
BioVie conducted SUNRISE-PD as a randomized, double-blind, placebo-controlled Phase 2 study designed to explore the biological and clinical effects of bezisterim in early-stage Parkinson’s disease. The trial enrolled 57 participants, who received either 20 mg of bezisterim twice daily or matching placebo for 12 weeks. Investigators assessed changes in movement, daily functioning, non-motor symptoms, sleep and inflammatory biomarkers using established clinical measures alongside exploratory assessments.
The most striking findings emerged among patients with baseline platelet counts exceeding 230 × 10⁹/L, a threshold representing the upper half of the study population. BioVie used these elevated counts as a potential indicator of increased systemic inflammation, allowing investigators to explore whether inflammatory status influenced the response to bezisterim.
In this prespecified subgroup, patients receiving bezisterim demonstrated statistically significant improvements on several components of the Movement Disorder Society–Unified Parkinson’s Disease Rating Scale, commonly abbreviated as MDS-UPDRS. The scale evaluates different aspects of Parkinson’s disease, including non-motor experiences, everyday activities and motor function.
For MDS-UPDRS Part I, which assesses non-motor experiences of daily living, scores changed by -1.62 points in the bezisterim group compared with an increase of 1.86 points among placebo recipients. The difference was statistically significant, with a p-value of 0.0124 and a reported Cohen’s d effect size of -1.33.
Motor examination scores, measured through MDS-UPDRS Part III, also favored bezisterim. The treatment group recorded a change of -1.32 points compared with an increase of 1.26 points in the placebo group, producing a p-value of 0.0265. Total MDS-UPDRS scores similarly favored bezisterim, with changes of -1.23 versus +1.21 and a p-value of 0.0006.
These findings suggest that patients with higher baseline inflammatory markers may experience improvements across several dimensions of Parkinson’s disease. However, the reported subgroup results require replication, and the trial was not large enough to establish definitively whether platelet counts can reliably predict treatment response.
Why could inflammation markers help identify Parkinson’s patients most likely to benefit?
Parkinson’s disease is a progressive neurological disorder characterized by the deterioration of dopamine-producing neurons, particularly within brain regions involved in movement control. Although tremor, stiffness and slowed movement are among its most recognizable symptoms, the condition also causes sleep disturbances, fatigue, cognitive difficulties, mood changes and autonomic dysfunction.
Growing research interest has focused on the potential contribution of inflammation to these processes. Neuroinflammatory activity and systemic metabolic disturbances may interact with neuronal injury, potentially influencing disease severity and progression. However, the relationship is complex, and inflammation has not been established as a single underlying cause of Parkinson’s disease.
Bezisterim, also known as NE3107, is an investigational oral compound designed to cross the blood-brain barrier and modulate pathways associated with inflammation and insulin resistance. BioVie believes its effects on signaling processes involving ERK, NF-κB and tumor necrosis factor-alpha could provide a therapeutic approach distinct from conventional dopamine-centered treatments.
The latest SUNRISE-PD analysis raises the possibility that patients with greater inflammatory activity may be more responsive to this mechanism. BioVie observed the strongest clinical effects in participants with higher platelet counts, which can sometimes reflect systemic inflammatory processes.
Nevertheless, platelet counts are influenced by numerous biological and medical factors and are not a specific diagnostic measure of neuroinflammation. The observed association therefore does not establish that inflammation caused the clinical differences or that platelet counts alone can identify appropriate patients for treatment.
Clarence Ahlem, BioVie’s senior vice president and Parkinson’s disease program lead, indicated that the findings supported further investigation of anti-inflammatory treatment strategies for both motor and non-motor manifestations of Parkinson’s disease. He also emphasized the potential importance of identifying patient populations whose underlying biology may make them more responsive to bezisterim.
What did the Phase 2 findings reveal about daily functioning and overall clinical improvement?
Beyond individual symptom measurements, BioVie evaluated broader treatment effects using a Composite Benefit Score designed to capture changes across multiple clinically relevant domains. The assessment incorporated outcomes related to movement, non-motor symptoms and everyday functioning, providing an additional perspective on the drug’s potential effects.
In the overall modified intention-to-treat population, the Composite Benefit Score favored bezisterim, with a reported Cohen’s d effect size of -1.61 and a p-value of 0.0004. These results suggest a potentially meaningful overall treatment signal, although the composite measure requires further validation before it can be regarded as an established endpoint for regulatory decision-making.
According to BioVie, approximately 25% of patients receiving bezisterim achieved clinically meaningful improvement on the composite measure, compared with 4% receiving placebo. This represented a 21-percentage-point absolute difference, with the treatment group approximately 6.25 times as likely to meet the improvement threshold.
The company also reported clinically meaningful worsening in 14% of bezisterim-treated patients compared with 46% of placebo recipients. That corresponds to an absolute difference of 32 percentage points and an approximately 70% lower relative risk of worsening during the observation period.
These findings are encouraging because patients with Parkinson’s disease frequently experience substantial impairment from symptoms extending beyond motor dysfunction. Sleep problems, cognitive changes and difficulties performing everyday activities can significantly reduce quality of life even when movement-related symptoms are reasonably controlled.
However, the composite measure combines several outcomes, and improvements across such an index do not necessarily translate into equivalent benefits for every individual symptom. Its clinical significance will depend on whether the results can be replicated using prospectively defined endpoints in larger studies.
How safe was bezisterim and what are the limitations of the reported Phase 2 results?
BioVie reported that bezisterim was generally well tolerated during the 12-week SUNRISE-PD trial. Treatment-emergent adverse events occurred in 39.3% of participants receiving bezisterim compared with 51.7% receiving placebo, while no severe or serious adverse events were reported in either treatment group.
Only one potentially treatment-related adverse event was reported in each group, providing encouraging preliminary evidence concerning short-term tolerability. However, the small sample size limits the ability to detect uncommon adverse reactions, and the findings cannot establish the safety of prolonged treatment.
The trial’s relatively short duration also limits conclusions about disease progression. Parkinson’s disease develops over years, meaning that improvements observed during 12 weeks cannot demonstrate that a treatment prevents neuronal deterioration or changes long-term disability outcomes.
Another important limitation concerns the concentration of statistically significant findings within an inflammation-defined subgroup. Although the subgroup was prespecified, multiple clinical assessments and exploratory comparisons increase the importance of independent confirmation.
The study’s primary pharmacodynamic endpoint concerned changes in inflammatory biomarker indices, while the reported symptom improvements form part of a broader clinical analysis. These exploratory clinical outcomes should therefore not be interpreted as equivalent to the successful completion of a pivotal trial powered to demonstrate treatment efficacy.
The company’s biomarker observations also remain preliminary. Changes in inflammatory or neurodegeneration-associated proteins may support a proposed mechanism, but they are not established evidence that bezisterim slows Parkinson’s disease progression.
What comes next for BioVie as bezisterim moves toward Phase 3 Parkinson’s disease development?
BioVie is preparing a Phase 3 development strategy for bezisterim in early-stage Parkinson’s disease and has engaged with the U.S. Food and Drug Administration regarding an end-of-Phase 2 meeting. The company has proposed using MDS-UPDRS Part III, which measures motor function, as the primary endpoint in a future pivotal trial.
This approach could provide a more conventional measure of treatment effectiveness than exploratory composite assessments or inflammation-defined subgroup analyses. A larger study would also allow investigators to examine whether the clinical benefits observed in SUNRISE-PD are reproducible across a broader population.
Future trial design will need to address patient selection, treatment duration, statistical power and the potential role of inflammatory biomarkers. The company may also need to determine whether the strongest benefits are confined to patients with elevated inflammation or extend to other individuals with early-stage Parkinson’s disease.
Bezisterim is being investigated beyond Parkinson’s disease, including in Long COVID and Alzheimer’s disease. These programs share an interest in inflammation and metabolic dysfunction, but findings in one indication cannot establish effectiveness in another.
For patients and clinicians, the most important unanswered question is whether modulating inflammatory pathways can produce durable improvements in daily functioning and movement while also affecting the underlying course of Parkinson’s disease. The current findings provide preliminary evidence of symptomatic benefit in a selected subgroup, but they do not establish disease modification.
BioVie’s latest clinical presentation strengthens the case for continued development of bezisterim and highlights the possible value of inflammation-informed treatment strategies. The next decisive step will be a larger, appropriately controlled trial capable of determining whether those promising Phase 2 signals translate into reliable clinical benefits.
